Promosyon programı Roivant Sciences Ltd.
Şirket hakkında
Roivant Sciences Ltd., биофармацевтическая и технологическая компания в области здравоохранения, которая исследует и разрабатывает лекарства. Компания разрабатывает продукты-кандидаты для лечения различных терапевтических средств, в том числе солидных опухолей, серповидно-клеточных заболеваний, гипофосфатазии, онкологических злокачественных новообразований, псориаза, атопического дерматита, витилиго, гипергидроза, угрей, миастении, теплой аутоиммунной гемолитической анемии, тиреоидных заболеваний глаз, саркоидоза. и бактериемия золотистого стафилококка.
Daha fazla ayrıntıЦена ао | 11.57 |
---|---|
Сайт | https://roivant.com |
P/S | 91.52 |
P/BV | 1.06 |
EV/EBITDA | -5.11 |
ISIN | BMG762791017 |
Число акций ао | 0.71279 млрд |
Выручка | 0.0023 |
EBITDA | 0.1381 |
P/E | 1.87 |
Валюта | usd |
IPO date | 2021-10-01 |
Sector | Health Care |
Industry | Biotechnology |
Валюта отчета | usd |
Günlük fiyat değişimi: | 0% (11.9) |
---|---|
Haftalık fiyat değişimi: | +6.16% (11.21) |
Aylık fiyat değişimi: | -1.82% (12.12) |
3 ayda fiyat değişimi: | +2.5% (11.61) |
Altı ayda fiyat değişimi: | +13.98% (10.44) |
Yıllık fiyat değişimi: | +16.78% (10.19) |
3 yılda fiyat değişimi: | +89.79% (6.27) |
Yılbaşından bu yana fiyat değişimi: | +31.93% (9.02) |
|
Hafife alma
|
Yeterlik
|
|||||||||||||||||||||||||||||||||||||
Temettüler
|
Görev
|
Büyüme dürtüsü
|
Kurumlar | Hacim | Paylaşmak, % |
---|---|---|
SB INVESTMENT ADVISERS (UK) LTD | 73 | 9.89 |
Viking Global Investors, L.P. | 69 | 9.39 |
Qvt Financial LP | 67 | 9.03 |
Blackrock Inc. | 36 | 4.9 |
Morgan Stanley | 36 | 4.82 |
FMR, LLC | 35 | 4.78 |
Rubric Capital Management LP | 20 | 2.71 |
State Street Corporation | 17 | 2.32 |
Patient Square Capital LP | 12 | 1.66 |
Woodline Partners LP | 11 | 1.51 |
ETF | Paylaşmak, % | Yıllık karlılık, % | Temettüler, % |
---|---|---|---|
Principal Healthcare Innovators ETF | 0.85791 | 618.4964157054 | 0.8416 |
iShares ESG Aware MSCI USA Small-Cap ETF | 0.0649 | 33.616398243045 | 1.49366 |
Invesco S&P MidCap 400 GARP ETF | 3.07188 | 33.881107312231 | 0.81 |
iShares Morningstar Small-Cap ETF | 0.11107 | 30.095066471445 | 1.60498 |
iShares Morningstar Small Cap Value ETF | 0.22508 | 26.701717953559 | 2.50476 |
iShares Russell 1000 Value ETF | 0.02034 | 27.836970474968 | 2.15361 |
iShares Russell Midcap ETF | 0.04371 | 33.221757322176 | 1.71565 |
iShares Russell Mid-Cap Value ETF | 0.0575 | 30.846698992913 | 2.03934 |
iShares Russell 3000 ETF | 0.00925 | 32.57283798366 | 1.43482 |
iShares Dow Jones U.S. ETF | 0.00987 | 32.373646209386 | 1.41797 |
iShares Morningstar Small-Cap ETF | 0.11107 | 391.25300933451 | 1.60498 |
iShares Morningstar Small-Cap Value ETF | 0.22508 | 227.12514109528 | 2.50476 |
iShares Russell 2500 ETF | 0.08046 | 32.983216025988 | 1.58987 |
iShares ESG Screened S&P Mid-Cap ETF | 0.20374 | 28.979354463507 | 1.537 |
Future Tech ETF | 0.85791 | 426.33969118983 | 0.8416 |
First Trust Health Care AlphaDEX Fund | 2.31974 | 15.127629071546 | 0.99486 |
Süpervizör | İş unvanı | Ödeme | Doğum yılı |
---|---|---|---|
Mr. Matthew Gline | CEO & Director | 1.77M | 1984 (40 yıllar) |
Dr. Eric Venker M.D., Pharm.D. | President & COO | 1.28M | 1987 (37 yıllar) |
Dr. Mayukh Sukhatme M.D. | President, Chief Investment Officer & Director | 1.72M | 1976 (48 yıllar) |
Mr. Richard Pulik | Chief Financial Officer | N/A | 1980 (44 yıl) |
Ms. Rakhi Kumar | Chief Accounting Officer | N/A | 1980 (44 yıl) |
Mr. Josh Chen | General Counsel | N/A | |
Ms. Kelly Graff | Head of People | N/A | |
Mr. Alex Gasner | Executive Vice President of Roivant Health | N/A | |
Mr. Drew Kramer | Chief Information Officer | ||
Dr. Matt Maisak | Chief Operating Officer of Roivant Platforms |
Web sitesi: https://roivant.com